ATE525084T1 - Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus - Google Patents

Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus

Info

Publication number
ATE525084T1
ATE525084T1 AT07872380T AT07872380T ATE525084T1 AT E525084 T1 ATE525084 T1 AT E525084T1 AT 07872380 T AT07872380 T AT 07872380T AT 07872380 T AT07872380 T AT 07872380T AT E525084 T1 ATE525084 T1 AT E525084T1
Authority
AT
Austria
Prior art keywords
treatment
botulinum neurotoxin
therapeutic treatments
aids virus
pain resulting
Prior art date
Application number
AT07872380T
Other languages
English (en)
Inventor
Christine Favre
Michel Auguet
De Lassauniere Pierre-Etienn Chabrier
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Application granted granted Critical
Publication of ATE525084T1 publication Critical patent/ATE525084T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07872380T 2006-12-22 2007-12-17 Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus ATE525084T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611244A FR2910327B1 (fr) 2006-12-22 2006-12-22 Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
PCT/FR2007/002091 WO2008090287A2 (fr) 2006-12-22 2007-12-17 Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida

Publications (1)

Publication Number Publication Date
ATE525084T1 true ATE525084T1 (de) 2011-10-15

Family

ID=38458082

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07872380T ATE525084T1 (de) 2006-12-22 2007-12-17 Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus

Country Status (6)

Country Link
US (1) US8921322B2 (de)
EP (1) EP2104510B1 (de)
AT (1) ATE525084T1 (de)
ES (1) ES2371785T3 (de)
FR (1) FR2910327B1 (de)
WO (1) WO2008090287A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
WO2010078242A1 (en) 2008-12-31 2010-07-08 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
SG177357A1 (en) 2009-06-25 2012-02-28 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
EP3372239B1 (de) 2012-05-30 2020-11-11 President and Fellows of Harvard College Manipuliertes botulinumneurotoxin
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
CN110072880B (zh) 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
ES2159624T3 (es) 1993-12-28 2001-10-16 Allergan Sales Inc Toxinas botulinicas para el tratamiento de la hiperhidrosis.
US6136551A (en) * 1995-04-24 2000-10-24 Allergan, Inc. Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
AU4904101A (en) 1999-12-08 2001-07-09 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP1586329A1 (de) * 2000-02-08 2005-10-19 Allergan, Inc. Pharmazeutische Zusammensetzungen mit botulinum Toxin
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
KR20030018827A (ko) 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20060178354A1 (en) * 2003-02-27 2006-08-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US20040247623A1 (en) * 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
GB2417419A (en) 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
GB2419526A (en) * 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
GB2416692A (en) 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
EP1799264A2 (de) * 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von migräne
AR053098A1 (es) 2004-11-04 2007-04-25 Toray Industries Analgesico derivado de morfinano
EP1863524A1 (de) * 2005-03-03 2007-12-12 Universite Catholique De Louvain Verfahren und zusammensetzungen zur behandlung von krebs
WO2006122123A2 (en) * 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
KR100726441B1 (ko) * 2005-11-22 2007-06-11 삼성전자주식회사 현상장치 및 이를 이용한 화상형성장치
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) * 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
JP4625869B2 (ja) * 2008-06-24 2011-02-02 パナソニック株式会社 表示装置

Also Published As

Publication number Publication date
EP2104510A2 (de) 2009-09-30
WO2008090287A2 (fr) 2008-07-31
EP2104510B1 (de) 2011-09-21
ES2371785T3 (es) 2012-01-10
US8921322B2 (en) 2014-12-30
FR2910327B1 (fr) 2013-04-26
WO2008090287A3 (fr) 2008-10-02
FR2910327A1 (fr) 2008-06-27
US20100029566A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA200971053A1 (ru) Способы лечения кожных язв
EP3773880C0 (de) Therapeutische modulation zur behandlung von blutzuckeranomalien, einschliesslich typ-2-diabetes, und/oder zur reduzierung von hba1c-spiegeln
WO2007100675A3 (en) Collagenase for treating cellulite
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
UA98125C2 (ru) Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний
PH12013501790B1 (en) Use of dpp iv inhibitors
MA32611B1 (fr) Procedes de traitement de la thalassemie
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
EP3590338A3 (de) Medizinische behandlungen basierend auf anamorelin
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
AR044315A1 (es) Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
EP2545929A4 (de) Mittel zur linderung oder heilung von chronischer prostatitis, interstitieller zystitis oder blasenentleerungsstörungen
ATE514422T1 (de) Osmolyte zur behandlung von allergisch bedingten atemwegserkrankungen
EA200970436A1 (ru) Соединения карбамата для лечения депрессии
WO2007100590A3 (en) Methods for treating cellulite

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties